Cyclooxygenase-1 and -2 in the different stages of Alzheimer's disease pathology

Current Pharmaceutical Design

Volumn 14, Issue 14, 2008, Pages 1419-1427

  Hoozemans, J J M ^a   Rozemuller, J M ^a   van Haastert, E S ^a   Veerhuis, R ^a   Eikelenboom, P ^a,b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Amyloid cell cycle proteins; Alzheimer's disease; Cyclooxygenase 1; Cyclooxygenase 2; Microglia; Neuroinflammation; Neuron; Non steroidal anti inflammatory drugs

Indexed keywords

ACETYLSALICYLIC ACID; AMYLOID BETA PROTEIN; ANTIINFLAMMATORY AGENT; ARACHIDONIC ACID; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETODOLAC; HYDROXYCHLOROQUINE; IBUPROFEN; INDOMETACIN; MELOXICAM; MISOPROSTOL; NAPROXEN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISONE; PROSTACYCLIN; PROSTAGLANDIN D2; PROSTAGLANDIN E2; PROSTAGLANDIN F2 ALPHA; PROSTAGLANDIN SYNTHASE; ROFECOXIB; SULINDAC; THROMBOXANE A2; UNINDEXED DRUG;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL CYCLE PROGRESSION; CLINICAL TRIAL; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG POTENCY; DRUG TREATMENT FAILURE; ENZYME ACTIVITY; ENZYME INHIBITION; GASTROINTESTINAL DISEASE; GENE EXPRESSION REGULATION; HUMAN; MICROGLIA; NEPHROTOXICITY; NEUROGENIC INFLAMMATION; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REGENERATION; REVIEW; STOMACH DISEASE; TREATMENT DURATION;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELL CYCLE PROTEINS; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; HUMANS; INFLAMMATION; NEURONS;

EID: 47249162481     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161208784480171     Document Type: Review

References (110)

1. Alzheimer A. Uber eine eigenartige Erkrankung der Hirnrinde. Algemeine Zeitschrift fur Psychiatrie und Psychisch-Gerichtliche Medizin 1907; 64: 146-8.
2. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, et al. Inflammation and Alzheimer's disease. Neurobiol Aging 2000; 21: 383-421.
3. Hoozemans JJ, Veerhuis R, Rozemuller AJ, Arendt T, Eikelenboom P. Neuronal COX-2 expression and phosphorylation of pRb precede p38 MAPK activation and neurofibrillary changes in AD temporal cortex. Neurobiol Dis 2004; 15: 492-9.
4. Yermakova AV, O'Banion MK. Downregulation of neuronal cyclooxygenase-2 expression in end stage Alzheimer's disease. Neurobiol Aging 2001; 22: 823-36.
5. Hoozemans JJ, Van Haastert ES, Veerhuis R, Arendt T, Scheper W, Eikelenboom P, et al. Maximal COX-2 and ppRb expression in neurons occurs during early Braak stages prior to the maximal activation of astrocytes and microglia in Alzheimer's disease. J Neuroinflamm 2005; 2: 27.
6. Arends YM, Duyckaerts C, Rozemuller JM, Eikelenboom P, Hauw JJ. Microglia, amyloid and dementia in alzheimer disease. A correlative study. Neurobiol Aging 2000; 21: 39-47.
7. Blalock EM, Geddes JW, Chen KC, Porter NM, Markesbery WR, Landfield PW. Incipient Alzheimer's disease: Microarray correlation analyses reveal major transcriptional and tumor suppressor responses. Proc Natl Acad Sci USA 2004; 101: 2173-8.
8. Eikelenboom P, Zhan SS, van Gool WA, Allsop D. Inflammatory mechanism in Alzheimer's disease. Trends Pharmacol Sci 1994; 15: 447-50.
9. Schmidt R, Schmidt H, Curb JD, Misaki K, White M Launer LJ. Early inflammation and dementia: A 25-year follow-up of the Honolulu-Asia Aging Study. Ann Neurol 2002; 52: 168-74.
10. Yaffe K, Lindquist K, Penninx BW, Simonsick EM, Pahor M, Kritchevsky S, et al. Inflammatory markers and cognition in well-functioning African-American and white elders. Neurology 2003; 61:76-80.
11. Engelhart MJ, Geerlings MI, Meijer J, Kiliaan A, Ruitenbcrg A, van Swieten JC, et al. Inflammatory proteins in plasma and the risk of dementia: The rotterdam study. Arch Neurol 2004; 61: 668-72.
12. Dik MG, Jonker C, Hack CE, Smit JH, Comijs HC, Eikelenboom P. Serum inflammatory proteins and cognitive decline in older persons. Neurology 2005; 64: 1371-7.
13. Rainero I, Bo M, Ferrero M, Valfre W, Vaula G, Pinessi L. Association between the interleukin-1alpha gene and Alzheimer's disease: A meta-analysis. Neurobiol Aging 2004; 25: 1293-8.
14. McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: A review of 17 epidemiologic studies. Neurology 1996; 47: 425-32.
15. in t'Veld BA, Ruitenberg A, Hofman A. Launer LJ, van Duijn CM, Stijnen T, et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med 2001; 345:1515-21.
16. Wyss-Coray T, Mucke L. Inflammation in neurodegenerative disease-a double-edged sword. Neuron 2002; 35: 419-32.
17. Hoozemans JJ, Veerhuis R, Rozemuller JM, Eikelenboom P. Neuroinflammation and regeneration in the early stages of Alzheimer's disease pathology. Int J Dev Neurosci 2006; 24: 157-65.
18. McGeer PL, McGeer EG. NSAIDs and Alzheimer disease: Epidemiological, animal model and clinical studies. Neurobiol Aging 2007; 28: 639-47
19. Vane JR, Botting RM. Mechanism of action of antiinflammatory drugs. Int J Tissue React 1998; 20: 3-15.
20. Herschman HR. Prostaglandin synthase 2. Biochim. Biophys Acta 1996; 1299: 125-40.
21. Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: Structural, cellular, and molecular biology. Annu Rev Biochem 2000; 69: 145-82.
22. Vane JR, Botting RM. Anti-inflammatory drug and their mechanism of action. Inflamm Res 1998; 47(Suppl 2): 78-87.
23. Rogers J, Kirby LC, Hempelman SR, Berry DL, McGeer PL, Kaszniak AW, et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology 1993; 43: 1609-11.
24. Scharf S, Mander A, Ugoni A, Vajda F, Christophidis N. A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease. Neurology 1999; 53: 197-201.
25. Aisen PS, Davis KL, Berg JD, Schafer K, Campbell K, Thomas RG, et al. A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study. Neurology 2000; 54: 588-93.
26. Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: A randomized controlled trial. JAMA 2003; 289: 2819-26.
27. van Gool WA, Weinstein HC, Scheltans P, Walstra GJ. Effect of hydroxychloroquine on progression of dementia in early Alzheimer's disease: An 18-month randomised, double-blind, placebo-controlled study. Lancet 2001; 358:455-60.
28. Reines SA, Block GA, Morris JC, Liu G, Nessly ML, Lines CR, et al. Rofecoxib: No effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology 2004; 62: 66-71.
29. Aisen PS. Results of a multicenter trial rofecoxib and naproxen in Alzheimer's disease. Neurobiol Aging 2002; 23: S429.
30. van Gool WA, Aisen PS, Eikelenboom P. Anti-inflammatory therapy in Alzheimer's disease: Is hope still alive? J Neurol 2003; 250: 788-92
31. Kitamura Y, Shimohama S, Koike H, Kakimura J, Matsuoka Y, Nomura Y, et al. Increased expression of cyclooxygenases and peroxisome proliferator-activated receptor-gamma in Alzheimer's disease brains. Biochem Biophys Res Commun 1999; 254:582-6.
32. Petrova TV, Akama KT, Van Eldik LJ. Cyclopenteone prostaglandins suppress activation of microglia: Down-regulation of inducible ducible nitric-oxide synthase by 15-deoxy-Deltal2,14-prostaglandin J2. Proc Natl Acad Sci USA 1999; 96: 4668-73.
33. Bernardo A, Levi G, Minghetti L. Role of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma) and its natural ligand 15-deoxy-Delta12, 14-prostaglandin J2 in the regulation of microglial functions. Eur J Neurosci 2000; 12: 2215-23.
34. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998; 391: 79-82.
35. Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 1998; 391: 82-6.
36. Camacho IE, Serneels L, Spittaels K, Merchiers P, Dominguez D, De Strooper B. Peroxisome proliferator-activated receptor gamma induces a clearance mechanism for the amyloid-beta peptide. J Neurosci 2004; 24: 10908-17.
37. Weggen S, Eriksen JL, Das P, Sagi SA, Wang R, Pietrzik CU, et al. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 2001; 414: 212-6.
38. Eriksen JL, Sagi SA, Smith TE, Weggen S, Das P, McLendon DC, et al. NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J Clin Invest 2003; 112: 440-9.
39. Morihara T, Chu T, Ubeda O, Beech W, Cole GM. Selective inhibition of Abeta42 production by NSAID R-enantiomers. J Neurochem 2002; 83: 1009-12.
40. Jantzen PT, Connor KE, DiCarlo G, Wenk GL, Wallace JL, Rojiani AM, et al. Microglial activation and beta -amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J Neurosci 2002; 22: 2246-54.
41. Weggen S, Eriksen JL, Sagi SA, Pietrzik CU, Ozols V, Fauq A, et al. Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid beta 42 production by direct modulation of gamma-secretase activity. J Biol Chem 2003; 278: 31831-7.
42. Beher D, Clarke EE, Wrigley JD, Martin AC, Nadin A, Churcher I, et al. Selected non-steroidal anti-inflammatory drugs and their derivatives target gamma-secretase at a novel site. Evidence for an allosteric mechanism. J Biol Chem 2004; 279: 43419-26.
43. Lleo A, Berezovska O, Herl L, Raju S, Deng A, Bacskai BJ, et al. Nonsteroidal anti-inflammatory drugs lower Abeta42 and change presenilin 1 conformation. Nat Med 2004; 10: 1065-6.
44. Gasparini L, Ongini E, Wenk G. Non-steroidal anti-inflammatory drugs (NSAIDs) in Alzheimer's disease: Old and new mechanisms of action. J Neurochem 2004; 91: 521-36.
45. Yamagata K, Andreasson KI, Kaufmann WE, Barnes CA, Worley PF. Expression of a mitogen-inducible cyclooxygenase in brain neurons: Regulation by synaptic activity and glucocorticoids. Neuron 1993; 11: 371-86.
46. Breder CD, Dewitt D, Kraig RP.Characterization of inducible cyclooxygenase in rat brain. J Comp Neurol 1995; 355: 296-315.
47. Yasojima K, Schwab C, McGeer EG, McGeer PL. Distribution of cyclooxygenase-1 and cyclooxygenase-2 mRNAs and proteins in human brain and peripheral organs. Brain Res 1999; 830: 226-36.
48. O'Banion MK. Cyclooxygenase-2: Molecular biology, pharmacology, and neurobiology. Crit Rev Neurobiol 1999; 13: 45-82.
49. Chen C, Magee JC, Bazan NG. Cyclooxygenase-2 regulates prostaglandin E2 signaling in hippocampal long-term synaptic plasticity. J Neurophysiol 2002; 87: 2851-7.
50. Kaufmann WE, Worley PF, Pegg J, Bremer M, Isakson P. COX-2, a synaptically induced enzyme, is expressed by excitatory neurons at postsynaptic sites in rat cerebral cortex. Proc Natl Acad Sci USA 1996; 93: 2317-21.
51. Shaw KN, Commins S, O'Mara SM. Deficits in spatial learning and synaptic plasticity induced by the rapid and competitive broad-spectrum cyclooxygenase inhibitor ibuprofen are reversed by increasing endogenous brain-derived neurotrophic factor. Eur J Neurosci 2003; 17: 2438-46.
52. Rall JM, Mach SA, Dash PK. Intrahippocampal infusion of a cyclooxygenase-2 inhibitor attenuated memory acquisition in rats. Brain Res 2003; 968: 273-6.
53. Yermakova AV, Rollins J, Callahan LM, Rogers J, O'Banion MK. Cyclooxygenase-1 in human Alzheimer and control brain: Quantitative analysis of expression by microglia and CA3 hippocampal neurons. J Neuropathol Exp Neurol 1999; 58: 1135-46.
54. Hoozemans JJ, Rozemuller AJ, Janssen I, de Groot CJ, Veerhuis R, Eikelenboom P. Cyclooxygenase expression in microglia and neurons in Alzheimer's disease and control brain. Acta Neuropathol (Berl) 2001; 101: 2-8.
55. Fiebich BL, Biber K, Lieb K, van Calker D, Berger M, Bauer J, et al. Cyclooxygenase-2 expression in rat microglia is induced by adenosine A2a-receptors. Glia 1996; 18: 152-60.
56. Minghetti L, Levi G. Induction of prostanoid biosynthesis by bacterial lipopolysaccharide and isoproterenol in rat microglial cultures. J Neurochem 1995; 65: 2690-8.
57. Bauer MK, Lieb K, Schulze-Osthoff K, Berger M, Gebicke-Haerter PJ, Bauer J, et al. Expression and regulation of cyclooxygenase-2 in rat microglia. Eur J Biochem 1997; 243: 726-31.
58. Hoozemans JJ, Veerhuis R, Janssen I, van Elk EJ, Rozemuller AJ, Eikelenboom P. The role of cyclo-oxygenase 1 and 2 activity in prostaglandin E(2) secretion by cultured human adult microglia: implications for Alzheimer's disease. Brain Res 2002; 951: 218-26.
59. Tomimoto H, Akiguchi I, Wakita K Lin JX, Budka H. Cyclooxygenase-2 is induced in microglia during chronic cerebral ischemia in humans. Acta Neuropathol (Berl) 2000; 99: 26-30.
60. Walsh DT, Perry VK Minghetti L. Cyclooxygenese-2 is highly expressed in microglial-like cells in a murine model of prion disease. Glia 2000; 29: 392-6.
61. Schwab JK Nguyen TD, Postler E, Meyermann R, Schluesener HJ. Selective accumulation of cyclooxygenase-1-expressing microglial cells/macrophages in lesions of human focal cerebral ischemia. Acta Neuropathol (Berl) 2000; 99: 609-14.
62. Doininger MH, Bekure-Nemariam K, Trautmann K, Morgalla M, Meyermann R, Schluesener HJ. Cyclooxygenase-1 and -2 in brains of patients who died with sporadic creutzfeldt-jakob disease. J Mol Neurosci 2003; 20: 25-30.
63. Maihofner C, Probst-Cousin S, Bergmann M, Neububer W, Neundorfer B, Heuss D. Expression and localization of cyclooxygenase-1 and -2 in human sporadic amyotrophic lateral sclerosis. Eur J Neurosci 2003; 18: 1527-34.
64. Seibert K, Masferrer JL. Role of inducible cyclooxygenase (COX-2) in inflammation. Receptor 1994; 4: 17-23.
65. Hoozemans JJ Veerhuis, Janssen L Rozermuller AJ, Eikelenboom P. Interleukin-1beta induced cyclooxygenase 2 expression and prostaglandin E2 secretion by human nemblastoma cells: Implications for Alzheimer's disease. Exp Gerontol 2001; 36: 559-70.
66. Griffin WS, Sheng JG, Roberts GW, Mrak RE. Interleukin-1 expression in different plaque types in Alzheimer's disease: Significance in plaque evolution. J. Neuropathol Exp Neurol 1995; 54: 276-81.
67. Blum-Degen D, Muller T, Kuhn W, Gerlach M, Przuntek K Riederer P. Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neurosci Lett 1995; 202: 17-20.
68. Hartung HP, Schafer B, Heininger K, Toyka KV. Recombinant interleukin-1 beta stimulates eicosanoid production in rat primary culture astrocytes. Brain Res 1989; 489: 113-9.
69. Blom MA, vanTwillert MG, de Vries SC, Engels F, Finch CE, Veerhuis R, et al. NSAIDS inhibit the IL-1 beta-induced IL-6 release from human post-mortem astrocytes: The involvement of prostaglandin E2. Brain Res 1997; 777: 210-8.
70. Mollace V, Colasanti M, Muscoli C, Lauro GM, Iannone M, Rotiroti D, et al. The effect of nitric oxide on cytokine-induced release of PGE2 by human cultured astroglial cells. Br J Pharmacol 1998; 124:742-6.
71. O'Banion MK, Miller JC, Chang JW, Kaplan MD, Coleman PD. Interleukin-1 beta induces prostaglandin G/H synthase-2 (cy-clooxygenase- 2) in primary maurine astrocyte cultures. J Neurochem 1996; 66:2532-40.
72. Fiebich BL, Hull M, Lieb K, Gyufko K, Berger M, Bauer J. Prostaglandin E2 induces interleukin-6 synthesis in human astrocytoma cells. J Neurochem 1997; 68: 704-9.
73. Fiebich BL, Schleicher S, Spleiss O, Czygan M, Hull M. Mechanisms of prostaglandin E2-induced interloukin-6 release in astrocytes: Possible involvement of EP4-like receptors, p38 mitogen-activated protein kinase and protein kinese C. J Neurochem. 2001; 79: 950-8.
74. Maslinska D, Wozniak R, Kaliszek A, Modelska I. Expression of cyclooxygenase-2 in astrocytes of human brain after global ischemia. Folia Neuropathol 1999; 37: 75-9.
75. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl) 1991; 82:239-59.
76. Braak H, Braak E. Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol Aging 1995; 16: 271-8.
77. Vane JR, Bakhle YS, Butting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 1998; 38: 97-120.
78. Oka A, Takashima S. Induction of cyclo-oxygenase 2 in brains of patients with Down's syndrome and dementia of Alzheimer type: Specific localization in affected neurones and axons. Neuroreport 1997; 8: 1161-4.
79. Pasinetti GM, Aisen PS. Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brain. Neuroscience 1998; 87: 319-24.
80. Ho L, Purohit D, Haroutunian V, Luterman JD, Willis F, Naslund J, et al. Neuronal cyclooxygenase 2 expression in the hippocampal formation as a function of the clinical progression of Alzheimer disease. Arch Neurol 2001; 58: 487-02.
81. Hoozemans JJ, Bruckner MK, Rozemuller AJ, Veerhuis R, Eikelenboom P, Arendt T. Cyclin D1 and cyclin E are co-localized with cyclo-oxygenase 2 (COX-2) in pyramidal neurons in Alzheimer disease temporal cortex. J Neuropathol Exp Neurol 2002; 61: 678-88.
82. Minghetti L. Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain diseases. J Neuropathol Exp Neurol 2004; 63: 901-10.
83. Combrinck M, Williams J, De Berardinis MA, Warden D, Puopolo M, Smith AD, et al. Levels of CSF prostaglandin E2, cognitive decline, and survival in Alzheimer's disease. J Neurol Neurosurg Psychiatry 2006; 77: 85-8.
84. Bazan NG, Lukiw WJ. Cyclooxygenase-2 and presenilin-1 gene expression induced by interleukin-1beta and amyloid beta 42 peptide is potentiated by hypoxia in primary human neural cells. J Biol Chem 2002; 277: 30359-67.
85. Fiebich BL, Mueksch B, Boehringer M, Hull M. Interleukin-1beta induces cyclooxygenase-2 and prostaglandin E(2) synthesis in human neuroblastoma cells: Ivolvement of p38 mitogen-activated protein kinase and nuclear factor-kappaB. J Neurochem 2000; 75: 2020-8.
86. Cotman CW, Hailer NP, Pfister KK, Soltesz I, Schachner M. Cell adhesion molecules in neural plasticity and pathology: Similar mechanisms, distinct organizations? Prog Neurobiol 1998; 55: 659-69.
87. Arendt T. Alzheimer's disease as a disorder of mechanisms underlying structural brain self-organization. Neuroscience 2001; 102: 723-65.
88. Grace EA, Busciglio J. Aberrant activation of focal adhesion proteins mediates fibrillar amyloid beta-induced neuronal dystrophy. J Neurosci 2003; 23: 493-502.
89. Arendt T, Rode L, Gartner U, Holzer M. Expression of the cyclin-dependent kinase inhibitor p16 in Alzheimer's disease. Neuroreport 1996; 7: 3047-9.
90. Nagy Z, Esiri MM, Cato AM, Smith AD. Cell cycle markers in the hippocampus in Alzheimer's disease. Acta Neuropathol (Berl) 1997; 94: 6-15.
91. Ranganathan S, Bowser R. Alterations in G(1) p S phase cell-cycle regulators during amyotrophic lateral sclerosis. Am J Pathol 2003; 162: 823-35.
92. Busser J, Geldmacher DS, Herrup K. Ectopic cell cycle proteins predict die sites of neuronal cell death in Alzheimer's disease brain. J Neurosci 1998; 18: 2801-7.
93. Gartner U, Holzer M, Arendt T. Elevated expression of p21ras is an early event in Alzheimer's disease and precedes neurofibrillary degeneration. Neuroscience 1999; 91: 1-5.
94. Yang Y, Mufson EJ. Herrup K. Neuronal cell death is preceded by cell cycle events at all stages of alzheimer's disease. J Neurosci 2003; 23: 2557-63.
95. Hoozemans JJ, Veerhuis P, Rozemuller AJ, Eikelenboom P. Non-steroidal anti-inflammatory drugs and cyclooxygeriase in Alzheimer's disease. Curr Drug Targets 2003; 4: 461-8.
96. Vincent I, Jicha G, Rosado M, Dickson DW. Aberrant expression of mitotic cdc2/cyclin B1 kinase in degenerating neurons of Alzheimer's disease brain. J Neurosci 1997; 17: 3588-98.
97. Kranenburg O. van der Eb AJ, Zantema A. Cyclin D1 is an essential mediator of apoptotic neuronal cell death. EMBO J 1996; 15: 46-54.
98. Copani A, Condorelli F, Caruso A, Vancheri C, Sala A, Giuffrida Stella AM, et al. Mitotic signaling by beta-amyloid causes neuronal death. FASEB J 1999; 13: 2225-34.
99. Liu DY, Greene LA. Neuronal apoptosis at the G1/S cell cycle checkpoint. Cell Tissue Res 2001; 305: 217-28.
100. Mirjany M, Ho L, Pasinetti GM. Role of cyclooxygenase-2 in neuronal cell cycle activity and glutamate-mediated excitotoxicity. J Pharmacol Exp Ther 2002; 301: 494-500.
101. Gouras GK, Almeida CG, Takahashi RH. Intraneuronal Abeta accumulation and origin of plaques in Alzheimer's disease. Neurobiol Aging 2005; 26: 1235-44.
102. Klyubin I, Walsh DM, Lemere CA, Cullen WK, Shankar GM, Betts V, et al. Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. Nat Med 2005; 11: 556-61.
103. Wu Q, Combs, Cannady SB, Geldmacher DS, Herrup K. Beta-amyloid activated microglia induce cell cycling and cell death in cultured cortical neurons. Neurobiol Aging 2000; 21: 797-806.
104. Xiang Z, Ho L, Valdellon J, Borchelt D, Kelley K, Spielman L, et al. Cyclooxygenase (COX)-2 and cell cycle activity in a transgenic mouse model of Alzheimer's disease neuropathology. Neurobiol Aging 2002; 23: 327-34.
105. Wu Chen R, Zhang Y, Rose ME, Graham SH. Cyclooxygenase-2 activity contributes to neuronal expression of cyclin D1 after anoxia/ischemia in vitro and in vivo. Brain Res Mol Brain Res 2004; 132:31-7.
106. Candelario-Jalil E, de Oliveira AC, Graf S, Bhatia HS, Hull M, Munoz E, et al. Resveratrol potently reduces prostaglandin E2 production and free radical formation in lipopolysaccharide-activated primary rat microglia. J Neuroinflamm 2007; 4: 25.
107. Stephenson DT, Lemere CA, Selkoe DJ, Clemens JA. Cytosolic phospholipase A2 (cPLA2) immunoreactivity is elevated in Alzheimer's disease brain. Neurobiol Dis 1996; 3: 51-63.
108. Cagnin A, Brooks DJ, Kennedy AM, Gunn RN, Myers R, Turkheimer FE, et al. In vivo measurement of activated microglia in dementia. Lancet 2001; 358: 461-7.
109. Lim GP, Yang F. Chu T, Chen P, Beech W, Teter B, et al. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J Neurosci 2000; 20: 5709-14.
110. Mackenzie IR, Munoz DG. Nonsteroidal anti-inflammatory drug use and Alzheimer-type pathology in aging. Neurology 1998; 50: 986-90.